Triple Negative Breast Cancer Trial (TNT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00532727 |
Recruitment Status : Unknown
Verified February 2019 by Institute of Cancer Research, United Kingdom.
Recruitment status was: Active, not recruiting
First Posted : September 20, 2007
Last Update Posted : February 20, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Drug: Carboplatin Drug: Docetaxel | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 400 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic or Recurrent Locally Advanced ER-, PR- and HER2- Breast Cancer. |
Actual Study Start Date : | January 2008 |
Actual Primary Completion Date : | March 2016 |
Estimated Study Completion Date : | March 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm A
Carboplatin
|
Drug: Carboplatin
AUC 6 every 3 weeks for six cycles (18 weeks) |
Active Comparator: Arm B
Docetaxel
|
Drug: Docetaxel
100mg/m2 every 3 weeks for six cycles (18 weeks) |
- Response: Response will be evaluated after three and six cycles of chemotherapy using modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria, with appropriate clinical assessment and radiological investigations. [ Time Frame: Time from start of treatment to 18 weeks ]
- Time to progression: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression [ Time Frame: Time from start of treatment until confirmation of progression ]
- Progression free survival: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression or death. [ Time Frame: Time from start of treatment until confirmation of progression or death ]
- Time to treatment failure: this will be defined as time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease as defined by RECIST [ Time Frame: Time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease ]
- Overall survival: this will be defined as time from randomisation until death from any cause in the intention to treat population [ Time Frame: Time from randomisation until death from any cause ]
- Toxicity will be assessed throughout the treatment period using the National Cancer Institute Common Terminology Criteria for Adverse Events version three (NCI CTCAE v3.0) [ Time Frame: Time from start of treatment to 18 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed ER-, PR-, primary breast cancer
- Histologically confirmed HER2- primary breast cancer
- Measurable confirmed metastatic or recurrent locally advanced disease unsuitable for local therapy but suitable for taxane chemotherapy
- Patients with stable, treated bain metastases will be eligible providing informed consent can be given and that other sites of measurable disease are present.
- Patients with bone metastases currently receiving bisphosphonates for palliation will be eligible providing informed consent can be given and that other sites of measurable disease are present
- ECOG Performance Status 0, 1, or 2
- Adequate haematology, biochemical indices (FBC, U & Es)
- LFTs = Normal bilirubin, AST and/or ALT = 3 x ULN if Alk Phos >5 x ULN (or an isolated elevation AST/ALT of ≤5 x ULN
- Adequate renal function - Creatinine clearance of >25mls per minute
- Written informed consent, able to comply with treatment and follow up
Exclusion Criteria:
- Original primary tumour or subsequent relapse known to be positive for any of ER, PR, or HER2 receptors
- Patients unfit for chemotherapy or those with neuropathy >grade 1 (sensory or motor)
- Known allergy to platinum compounds or to mannitol
- Known sensitivity to taxanes
- Patients with inoperable locally advanced disease suitable for local radiotherapy or an anthracycline containing regimen
- Previous chemotherapy for metastatic disease other than an anthracycline as in inclusion criteria above
- Previous exposure to a taxane in adjuvant chemotherapy within 12 months of trial entry
- Previous treatment with a taxane for recurrent locally advanced disease
- Previous treatment with a platinum chemotherapy drug
- LFTs = Abnormal bilirubin (> ULN), AST and/or ALT >3 X ULN and Alk Phos >5 x ULN (or an isolated elevation AST/ALT of >5 x ULN)
- Patients with a life expectancy of less than 3 months
- Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous call carcinoma of the skin, unless there has been a disease free interval of at least 10 years
- Previous or synchronous second breast cancer (unless also confirmed ER-, PR- and HER2-)
- Patients with bone limited disease
- Other serious uncontrolled medical conditions or concurrent medical illness likely to compromise life expectancy and/or the completion of trial therapy
- Pregnant, lactating or potentially childbearing women not using adequate contraception
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00532727
United Kingdom | |
Guy's and St Thomas' Hospital NHS Foundation Trust | |
London, United Kingdom, SE1 9RT |
Principal Investigator: | Andrew Tutt, MB ChB, MRCP, FRCR, PhD | King's College London |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Institute of Cancer Research, United Kingdom |
ClinicalTrials.gov Identifier: | NCT00532727 |
Other Study ID Numbers: |
ICR-CTSU/2006/10003 ISRCTN97330959 Main REC: 07/Q0603/67 CTA: 22138/0004/001-0001 EudraCT Number: 2006-004470-26 |
First Posted: | September 20, 2007 Key Record Dates |
Last Update Posted: | February 20, 2019 |
Last Verified: | February 2019 |
Breast Cancer Triple Negative |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Carboplatin |
Docetaxel Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |